Dr. Badreddin Edris is President and Chief Operating Officer of Beeline Medicines and brings deep experience building and scaling biotechnology companies from drug discovery through commercialization. Most recently, he served as Chief Operating Officer of SpringWorks Therapeutics, where during his tenure, he played a central role in capital formation, strategic partnerships, operational scale-up, clinical development strategy, two global regulatory approvals and launches of category-leading medicines, and ultimately, the company’s sale to Merck KGaA, Darmstadt, Germany.
Previously, Dr. Edris was an investment professional on the private equity team at OrbiMed, where he focused on venture investments and company creation, including co-founding Silverback Therapeutics and Edgewise Therapeutics. Earlier in his career, he was a management consultant at Bain & Company, advising pharmaceutical and biotechnology companies. He currently serves on the Board of Edgewise Therapeutics and as a Venture Partner at The Column Group.
Dr. Edris received his Ph.D. in genetics from Stanford University School of Medicine, where he was an NSF research fellow.
